Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

Crypto News: Pepeto Exchange Upgrade While XRP Price Might Reach $5 Soon - Here Is What Every Holder Need To Know

View original at globenewswire.com
Crypto News: Pepeto Exchange Upgrade While XRP Price Might Reach $5 Soon - Here Is What Every Holder Need To Know Dubai, UAE, March 26, 2026 (GLOBE NEWSWIRE) -- The Pepeto project just delivered a fresh security upgrade across its exchange while the XRP price prediction improves on real catalysts…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • XRP price projection of $5 based on settlement volume growth

    60% confidence

  • Oil above $100, the Fed holding rates, and compressed risk appetite are all temporary

    60% confidence

  • Conservative XRP price scenario puts XRP between $1.80 and $2.50 by year end if the CLARITY Act passes and rate cuts arrive

    60% confidence

  • Pepeto cofounder took Pepe from nothing to $11 billion on community alone

    60% confidence

  • XRP price target of $2.80

    60% confidence

  • Every crypto bull run in history started after a rate cut

    60% confidence

  • XRP price prediction is building toward $5 to $10

    60% confidence

  • XRP at $5 means a 3.5x return on an $85 billion market cap over quarters or years

    60% confidence

  • Pepeto Binance listing drops very soon

    60% confidence

Data points we hold from this source

XRP · ema 50 day1.49 USD
XRP · futures open interest2.42 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Crypto News: Pepeto Exchange Upgrade While XRP Price Might Reach $5 Soon - Here Is What Every Holder Need To Know — Source | Via News | ViaNews EU